Can carbon nanotube-liposome conjugates address the issues associated with carbon nanotubes in drug delivery? Academic Article uri icon

abstract

  • The metallic catalyst could interact with oxidative species in cells, and cause oxidative damage to healthy tissues. Functionalization also turns the CNTs more hydrophilic and, as such, more water soluble and more biocompatible [7]. Last, the functionalization process shortens the CNTs [15], which enhances their clearance and dictates the ability of phagocytic cells to completely internalize and process them. The longer the CNTs are the more difficult it is to phagocytose them. Long CNTs (> 15 µm) could induce chronic release of inflammatory mediators. In order to further reduce the toxic effect, we employed liposome formulation that is already being used in the clinics for treatment of human cancers. It is used as an anticancer drug (Doxil®) for various types of cancers, such as ovarian cancer [16]. Evaluation of the CLC toxicity was performed by in vitro cell viability testing [5]. CLC at a …

publication date

  • April 1, 2013